Halozyme Therapeutics, Inc. (NASDAQ:HALO) Short Interest Up 11.6% in September

Halozyme Therapeutics, Inc. (NASDAQ: HALO – Get Rating) benefited from a surge in short-term interest during September. As of September 30, there was short interest totaling 12,110,000 shares, an increase of 11.6% from the total of 10,850,000 shares as of September 15. About 8.9% of the stock’s shares are sold short. Based on an average trading volume of 1,330,000 shares, the days-to-cover ratio is currently 9.1 days.

Halozyme Therapeutics trades up 2.2%

Halozyme Therapeutics stock opened Monday at $44.17. The company has a 50-day moving average of $41.37 and a 200-day moving average of $43.56. The company has a current ratio of 2.72, a quick ratio of 2.23 and a debt ratio of 3.91. Halozyme Therapeutics has a 12 month minimum of $31.36 and a 12 month maximum of $52.98. The company has a market capitalization of $6.09 billion, a price/earnings ratio of 17.46, a P/E/G ratio of 0.73 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last reported quarterly results on Tuesday, August 9. The biopharmaceutical company reported EPS of $0.50 for the quarter, beating the consensus estimate of $0.47 by $0.03. The company posted revenue of $152.37 million for the quarter, versus a consensus estimate of $156.00 million. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 101.73%. The company’s revenue increased by 11.7% compared to the same quarter last year. In the same quarter last year, the company posted EPS of $0.63. As a group, research analysts predict that Halozyme Therapeutics will post earnings per share of 1.92 for the current year.

Analyst upgrades and downgrades

A number of brokerages have recently commented on HALO. StockNews.com began covering Halozyme Therapeutics shares in a research report on Wednesday, October 12. They issued a “hold” rating for the company. Morgan Stanley began covering Halozyme Therapeutics shares in a Friday, September 9 report. They set an “overweight” rating and a price target of $50.00 on the stock. One financial analyst gave the stock a hold rating and six gave the stock a buy rating. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $52.00.

Hedge funds weigh in on Halozyme Therapeutics

Several hedge funds and other institutional investors have recently increased or reduced their stakes in the stock. First Horizon Advisors Inc. increased its stake in Halozyme Therapeutics by 188.8% during the second quarter. First Horizon Advisors Inc. now owns 722 shares of the biopharmaceutical company worth $32,000 after buying 472 additional shares in the last quarter. Meeder Asset Management Inc. increased its stake in Halozyme Therapeutics by 223.6% in the second quarter. Meeder Asset Management Inc. now owns 741 shares of the biopharmaceutical company valued at $33,000 after buying an additional 512 shares last quarter. Brown Brothers Harriman & Co. acquired a new position in Halozyme Therapeutics stock during Q2 worth approximately $35,000. San Luis Wealth Advisors LLC purchased a new equity stake in Halozyme Therapeutics in the first quarter valued at $36,000. Finally, Selective Wealth Management Inc. bought a new stock position in Halozyme Therapeutics in Q2 worth $44,000. 91.72% of the shares are held by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

(Get a rating)

Halozyme Therapeutics, Inc operates as a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan and internationally. The Company’s products are based on ENHANZE drug delivery technology, a patented recombinant human hyaluronidase (rHuPH20) enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules. , as well as small molecules and fluids.

Recommended Stories

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider Halozyme Therapeutics, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Halozyme Therapeutics didn’t make the list.

Although Halozyme Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Comments are closed.